1. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
- Author
-
Rutgeerts, Paul J, Fedorak, Richard N, Hommes, Daan W, Sturm, Andreas, Baumgart, Daniel C, Bressler, Brian, Schreiber, Stefan, Mansfield, John C, Williams, Marna, Tang, Meina, Visich, Jennifer, Wei, Xiaohui, Keir, Mary, Luca, Diana, Danilenko, Dimitri, Egen, Jackson, and O'Byrne, Sharon
- Subjects
Inflammatory Bowel Disease ,Biotechnology ,Clinical Trials and Supportive Activities ,Clinical Research ,Digestive Diseases ,Autoimmune Disease ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Adolescent ,Adult ,Aged ,Antibodies ,Monoclonal ,Antibodies ,Monoclonal ,Humanized ,Colitis ,Ulcerative ,Dose-Response Relationship ,Drug ,Double-Blind Method ,Female ,Gastrointestinal Agents ,Humans ,Infusions ,Intravenous ,Injections ,Subcutaneous ,Male ,Middle Aged ,Severity of Illness Index ,Treatment Outcome ,Young Adult ,Etrolizumab ,rhuMAb 7 ,ulcerative colitis ,drug development ,safety ,pharmacokinetics ,IBD clinical ,IBD basic research ,IBD ,IBD models ,apoptosis ,cell cycle ,immunology ,inflammatory bowel disorders ,dendritic cells ,Crohn's disease ,cytokines ,genetics ,signal transduction ,IBD-genetics ,antibody targeted therapy ,arthritis ,autoimmune disease ,integrins ,IBD–genetics ,rhuMAb β7 ,Clinical Sciences ,Paediatrics and Reproductive Medicine ,Gastroenterology & Hepatology - Abstract
ObjectiveEtrolizumab (rhuMAb β7, anti-β7, PRO145223) is a humanised monoclonal antibody targeting the β7 subunit of the heterodimeric integrins α4β7 and αEβ7, which are implicated in leucocyte migration and retention in ulcerative colitis (UC). This randomised phase I study evaluated the safety and pharmacology of etrolizumab in patients with moderate to severe UC.DesignIn the single ascending dose (SAD) stage, etrolizumab (0.3, 1.0, 3.0, 10 mg/kg intravenous, 3.0 mg/kg subcutaneous (SC) or placebo) was administered 4:1 (n=25) in each cohort. In the multiple dose (MD) stage, new patients received monthly etrolizumab (0.5 mg/kg SC (n=4), 1.5 mg/kg SC (n=5), 3.0 mg/kg SC (n=4), 4.0 mg/kg intravenous (n=5)) or placebo (n=5). The pharmacokinetics was studied and Mayo Clinic Score evaluated at baseline, day 29 (SAD), and days 43 and 71 (MD).ResultsIn the SAD stage, there were no dose limiting toxicities, infusion or injection site reactions. Two impaired wound healing serious adverse events occurred in two patients receiving etrolizumab. In the MD stage, there were no dose limiting toxicities, and no infusion or injection site reactions. Headache was the most common adverse event, occurring more often in etrolizumab patients. Antietrolizumab antibodies were detected in two subjects. The duration of β7 receptor full occupancy was dose related. A clinical response was observed in 12/18 patients, and clinical remission in 3/18 patients treated with etrolizumab in the MD stage, compared with 4/5 and 1/5 placebo patients, respectively.ConclusionEtrolizumab is well tolerated in moderate to severe UC. Further investigation is warranted.
- Published
- 2013